Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.


Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
04 Sep 2019
Historique:
received: 06 02 2019
accepted: 22 05 2019
entrez: 6 9 2019
pubmed: 6 9 2019
medline: 15 2 2020
Statut: epublish

Résumé

To determine the feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation (Hypo-IGRT) in locally advanced node-positive non-small cell lung cancer patients with highly compromised pulmonary function. Eight highly-selected and closely monitored patients with highly diminished pulmonary function (FEV1 ≤ 1.0 L and/or DLCO-SB ≤ 40% and/or on long-term oxygen therapy) were treated with Hypo-IGRT. Planning was based on 18F-FDG-PET/CT and 4D-CT in the treatment position. Hypo-IGRT was delivered to a total dose of 45 Gy (ICRU) in 15 daily fractions under strict image-guidance. Vital capacity (VC), forced expiratory volume in 1 s (FEV1), and single-breath diffusing capacity of the lung for CO (DLCO-SB) were analyzed prior to, 3 and 6 months after Hypo-IGRT. Eight patients with stage IIIA-C NSCLC (8th TNM Ed.) completed Hypo-IGRT. The median follow-up was 29.4 months. The median age was 64 years. Four, three and one patient(s) presented with COPD GOLD IV, III and II, respectively and 5 patients (63%) were on long-term oxygen therapy. The median PTV was 226.9 cc (range: 100.17-379.80 cc). Median PFS and OS were 19 and 34.3 months. The 6 months and 1-year OS rates were 100, 87.5%, respectively. The 6- and 12- months PFS rates were 87.5 and 52.5%. Three patients developed local failure. Median initial VC, FEV1 and DLCO-SB was 1.69 L/64.8% predicted (range: 1.36-2.66 L/33-80%), 1 L/39.4% predicted (range:0.78-1.26 L/28-60% predicted) and 33.3% (range: 13.3-54%) predicted, respectively. Median values for VC, FEV1, DLCO-SB 3 and 6 months after Hypo-IGRT were 2.05 L/56.35% predicted (range: 1.34-2.33 L/47-81.5%), 1.08 L/47.5% predicted (range: 0.74-1.60 L/30.8-59.59%), 38.55% (range: 24-68%) and 1.64 L/66% predicted (range: 1.41-2.79/35.5-75.5%), 1.0 L/47% predicted (range: 0.65-1.28 L/24.5-54.10%), 31% (range: 27-43%), respectively. Mean lung dose was 9.4 Gy (range: 5.3-11.6 Gy) and V20 for both lungs was 15% (range: 6-19%). Mean esophageal dose was 12.76 Gy (range: 2.1-26.7 Gy). There was no case of grade 2 or higher radiation pneumonitis. Four patients developed grade 2 radiation esophagitis. Hypo-IGRT can be considered for individual and closely monitored patients with locally advanced node-positive NSCLC with highly compromised pulmonary function. No severe pulmonary toxicity and significant decline of pulmonary function parameters was observed in our cohort. Currently, this protocol is being assessed in an ongoing single-centre prospective study.

Sections du résumé

BACKGROUND BACKGROUND
To determine the feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation (Hypo-IGRT) in locally advanced node-positive non-small cell lung cancer patients with highly compromised pulmonary function.
METHOD METHODS
Eight highly-selected and closely monitored patients with highly diminished pulmonary function (FEV1 ≤ 1.0 L and/or DLCO-SB ≤ 40% and/or on long-term oxygen therapy) were treated with Hypo-IGRT. Planning was based on 18F-FDG-PET/CT and 4D-CT in the treatment position. Hypo-IGRT was delivered to a total dose of 45 Gy (ICRU) in 15 daily fractions under strict image-guidance. Vital capacity (VC), forced expiratory volume in 1 s (FEV1), and single-breath diffusing capacity of the lung for CO (DLCO-SB) were analyzed prior to, 3 and 6 months after Hypo-IGRT.
RESULT RESULTS
Eight patients with stage IIIA-C NSCLC (8th TNM Ed.) completed Hypo-IGRT. The median follow-up was 29.4 months. The median age was 64 years. Four, three and one patient(s) presented with COPD GOLD IV, III and II, respectively and 5 patients (63%) were on long-term oxygen therapy. The median PTV was 226.9 cc (range: 100.17-379.80 cc). Median PFS and OS were 19 and 34.3 months. The 6 months and 1-year OS rates were 100, 87.5%, respectively. The 6- and 12- months PFS rates were 87.5 and 52.5%. Three patients developed local failure. Median initial VC, FEV1 and DLCO-SB was 1.69 L/64.8% predicted (range: 1.36-2.66 L/33-80%), 1 L/39.4% predicted (range:0.78-1.26 L/28-60% predicted) and 33.3% (range: 13.3-54%) predicted, respectively. Median values for VC, FEV1, DLCO-SB 3 and 6 months after Hypo-IGRT were 2.05 L/56.35% predicted (range: 1.34-2.33 L/47-81.5%), 1.08 L/47.5% predicted (range: 0.74-1.60 L/30.8-59.59%), 38.55% (range: 24-68%) and 1.64 L/66% predicted (range: 1.41-2.79/35.5-75.5%), 1.0 L/47% predicted (range: 0.65-1.28 L/24.5-54.10%), 31% (range: 27-43%), respectively. Mean lung dose was 9.4 Gy (range: 5.3-11.6 Gy) and V20 for both lungs was 15% (range: 6-19%). Mean esophageal dose was 12.76 Gy (range: 2.1-26.7 Gy). There was no case of grade 2 or higher radiation pneumonitis. Four patients developed grade 2 radiation esophagitis.
CONCLUSION CONCLUSIONS
Hypo-IGRT can be considered for individual and closely monitored patients with locally advanced node-positive NSCLC with highly compromised pulmonary function. No severe pulmonary toxicity and significant decline of pulmonary function parameters was observed in our cohort. Currently, this protocol is being assessed in an ongoing single-centre prospective study.

Identifiants

pubmed: 31484542
doi: 10.1186/s13014-019-1304-2
pii: 10.1186/s13014-019-1304-2
pmc: PMC6727570
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

163

Références

Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1053-6
pubmed: 10421538
Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1475-82
pubmed: 11121651
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):324-33
pubmed: 16168827
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60
pubmed: 21903745
Radiat Oncol. 2012 Mar 15;7:33
pubmed: 22420631
Lancet Oncol. 2012 Aug;13(8):802-9
pubmed: 22727222
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1092-9
pubmed: 24661663
Clin Lung Cancer. 2015 Mar;16(2):71-9
pubmed: 25450876
Clin Lung Cancer. 2015 Mar;16(2):156-63
pubmed: 25467928
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):72-81
pubmed: 26279026
J Thorac Oncol. 2015 Dec;10(12):1762-9
pubmed: 26334751
Anticancer Res. 2015 Oct;35(10):5693-700
pubmed: 26408745
Clin Lung Cancer. 2016 Nov;17(6):588-594
pubmed: 27378172
JAMA Oncol. 2017 Oct 1;3(10):1358-1365
pubmed: 28570742
J Thorac Oncol. 2017 Oct;12(10):1561-1570
pubmed: 28648948
Radiat Oncol J. 2017 Jun;35(2):180-184
pubmed: 28712277
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658

Auteurs

Chukwuka Eze (C)

Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany. Chukwuka.Eze@med.uni-muenchen.de.

Julian Taugner (J)

Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.

Olarn Roengvoraphoj (O)

Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.

Nina-Sophie Schmidt-Hegemann (NS)

Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.

Lukas Käsmann (L)

Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.

Cherylina Wijaya (C)

Department of Pulmonology, Asklepios-Fachkliniken München-Gauting, Munich, Germany.

Claus Belka (C)

Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.

Farkhad Manapov (F)

Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH